Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 612, Issue 1-3, Pages 167-173Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2009.03.066
Keywords
Arcuate nucleus; Feeding; Food intake; Growth hormone secretagogue; Hypothalamus; Neuropeptide Y
Categories
Funding
- Swedish Medical Research Council [VR k2007-54x-20328-013]
- European Commission 6th Framework [EC LSHM-CT-2003-503041]
- Novo Nordisk Fonden
- ALF Goteborg [SU7601]
- Swedish Foundation for Strategic Research to Sahlgrenska Center for Cardiovascular and Metabolic Research [A305-188]
Ask authors/readers for more resources
Here we provide the first pharmacological exploration of the impact of acute central nervous system exposure to three recently developed ghrelin receptor (GHS-R1A) ligands on food intake and on the electrical activity of the target cells for ghrelin in the hypothalamus. Central (i.c.v) injection of GHS-R1A antagonists to rats suppressed food intake induced by i.c.v ghrelin injection (1 mu g) in a dose-dependent manner with a total blockade at concentraions of 0.4 mu g and 8 mu g for JMV 3002 and JMV 2959 respectively. JMV 2810, a partial agonist, also suppressed ghrelin-induced food intake (range: 0.02-2 mu g). Moreover all three compounds reduced fasting-induced food intake in rats (i.e. the amount of food eaten during the first hour of food exposure after a 16 h fast). At the single cell level we also explored the effects of the compounds to suppress ghrelin (0.5 mu M)-induced changes in electrical activity of arcuate nucleus cells recorded extracellularly in a slice preparation. Preincubation followed by perfusion with the GHS-R1A ligands suppressed the responsiveness of arcuate cells to ghrelin. Thus, the recently developed GHS-R1A ligands (JMV 3002, 2959 and 2810) suppress ghrelin-induced and fasting-induced food intake at the level of the central nervous system. This appears to be mediated, at least in part, by a modulation of the activity of ghrelin-responsive arcuate nucleus cells. As the central ghrelin signalling system has emerged as an important pro-obesity target, it will be important to establish the efficacy of these GHS-R1A ligands to reduce fast mass in clincal studies. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available